219 related articles for article (PubMed ID: 32070131)
21. Psychometrics and validation of the EQ-5D-5L instrument in individuals with ischemic stroke in Lithuania.
Taroza S; Burkauskas J; Mickuviene N; Kazukauskiene N; Podlipskyte A
Front Psychol; 2023; 14():1284859. PubMed ID: 38125861
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of the EQ-5D-3L and 5L versions in low back pain patients.
Garratt AM; Furunes H; Hellum C; Solberg T; Brox JI; Storheim K; Johnsen LG
Health Qual Life Outcomes; 2021 May; 19(1):155. PubMed ID: 34049574
[TBL] [Abstract][Full Text] [Related]
23. Which Questionnaire Should Be Used to Measure Quality-of-Life Utilities in Patients with Acute Leukemia? An Evaluation of the Validity and Interpretability of the EQ-5D-5L and Preference-Based Questionnaires Derived from the EORTC QLQ-C30.
van Dongen-Leunis A; Redekop WK; Uyl-de Groot CA
Value Health; 2016; 19(6):834-843. PubMed ID: 27712712
[TBL] [Abstract][Full Text] [Related]
24. Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L in psoriasis patients.
Poór AK; Rencz F; Brodszky V; Gulácsi L; Beretzky Z; Hidvégi B; Holló P; Kárpáti S; Péntek M
Qual Life Res; 2017 Dec; 26(12):3409-3419. PubMed ID: 28875430
[TBL] [Abstract][Full Text] [Related]
25. Association between in-hospital frailty and health-related quality of life after stroke: the Nor-COAST study.
Wæhler IS; Saltvedt I; Lydersen S; Fure B; Askim T; Einstad MS; Thingstad P
BMC Neurol; 2021 Mar; 21(1):100. PubMed ID: 33663430
[TBL] [Abstract][Full Text] [Related]
26. The construct validity and responsiveness of the EQ-5D-5L, AQL-5D and a bespoke TTO in acute asthmatics.
Crossman-Barnes CJ; Sach T; Wilson A; Barton G
Qual Life Res; 2020 Mar; 29(3):619-627. PubMed ID: 31676971
[TBL] [Abstract][Full Text] [Related]
27. The feasibility, repeatability, validity and responsiveness of the EQ-5D-3L in Krio for patients with stroke in Sierra Leone.
Youkee D; Pessima S; Sackley C; Soley-Bori M; Deen GF; Marshall IJ
Health Qual Life Outcomes; 2024 Mar; 22(1):29. PubMed ID: 38549069
[TBL] [Abstract][Full Text] [Related]
28. Validity of EQ-5D-5L health-related quality of life questionnaire in self-reported diabetes: evidence from a general population survey.
Jankowska A; Młyńczak K; Golicki D
Health Qual Life Outcomes; 2021 May; 19(1):138. PubMed ID: 33952271
[TBL] [Abstract][Full Text] [Related]
29. Comparison of the PROMIS Preference Score (PROPr) and EQ-5D-5L Index Value in General Population Samples in the United Kingdom, France, and Germany.
Klapproth CP; Sidey-Gibbons CJ; Valderas JM; Rose M; Fischer F
Value Health; 2022 May; 25(5):824-834. PubMed ID: 35500951
[TBL] [Abstract][Full Text] [Related]
30. Measuring health-related quality of life in chronic obstructive pulmonary disease: properties of the EQ-5D-5L and PROMIS-43 short form.
Lin FJ; Pickard AS; Krishnan JA; Joo MJ; Au DH; Carson SS; Gillespie S; Henderson AG; Lindenauer PK; McBurnie MA; Mularski RA; Naureckas ET; Vollmer WM; Lee TA;
BMC Med Res Methodol; 2014 Jun; 14():78. PubMed ID: 24934150
[TBL] [Abstract][Full Text] [Related]
31. Comparison of the preference-based EQ-5D-5L and SF-6D in patients with end-stage renal disease (ESRD).
Yang F; Lau T; Lee E; Vathsala A; Chia KS; Luo N
Eur J Health Econ; 2015 Dec; 16(9):1019-26. PubMed ID: 25519850
[TBL] [Abstract][Full Text] [Related]
32. Psychometric comparison of the standard EQ-5D to a 5 level version in cancer patients.
Pickard AS; De Leon MC; Kohlmann T; Cella D; Rosenbloom S
Med Care; 2007 Mar; 45(3):259-63. PubMed ID: 17304084
[TBL] [Abstract][Full Text] [Related]
33. Comparative performance of the EQ-5D-5L and SF-6D index scores in adults with type 2 diabetes.
Sayah FA; Qiu W; Xie F; Johnson JA
Qual Life Res; 2017 Aug; 26(8):2057-2066. PubMed ID: 28364183
[TBL] [Abstract][Full Text] [Related]
34. Sensitivity of the EQ-5D-5L for fatigue and cognitive problems and their added value in Q-fever patients.
Geraerds AJLM; Polinder S; Spronk I; Olde Loohuis AGM; de Groot A; Bronner MB; Haagsma JA
Qual Life Res; 2022 Jul; 31(7):2083-2092. PubMed ID: 35091984
[TBL] [Abstract][Full Text] [Related]
35. Comparing EQ-5D-3L and EQ-5D-5L performance in common cancers: suggestions for instrument choosing.
Zhu J; Yan XX; Liu CC; Wang H; Wang L; Cao SM; Liao XZ; Xi YF; Ji Y; Lei L; Xiao HF; Guan HJ; Wei WQ; Dai M; Chen W; Shi JF
Qual Life Res; 2021 Mar; 30(3):841-854. PubMed ID: 32930993
[TBL] [Abstract][Full Text] [Related]
36. Healthcare consumer acceptability of routine use of the EQ-5D-5L in clinical care: a cross-sectional survey.
Snowdon DA; Collyer TA; Marsh L; Srikanth V; Beare R; Baber S; Naude K; Andrew NE
Qual Life Res; 2024 May; 33(5):1307-1321. PubMed ID: 38321194
[TBL] [Abstract][Full Text] [Related]
37. Comparing the measurement equivalence of EQ-5D-5L across different modes of administration.
Mulhern B; O'Gorman H; Rotherham N; Brazier J
Health Qual Life Outcomes; 2015 Nov; 13():191. PubMed ID: 26612336
[TBL] [Abstract][Full Text] [Related]
38. Translation, validity and reliability of the British Sign Language (BSL) version of the EQ-5D-5L.
Rogers KD; Pilling M; Davies L; Belk R; Nassimi-Green C; Young A
Qual Life Res; 2016 Jul; 25(7):1825-34. PubMed ID: 26887955
[TBL] [Abstract][Full Text] [Related]
39. Comparing the measurement properties of the EQ-5D-5L and the EQ-5D-3L in hypertensive patients living in rural China.
Jiang J; Hong Y; Zhang T; Yang Z; Lin T; Liang Z; Lu P; Liu L; Wang B; Xu Y; Luo N
Qual Life Res; 2021 Jul; 30(7):2045-2060. PubMed ID: 33821418
[TBL] [Abstract][Full Text] [Related]
40. Psychometric properties of the EQ-5D-5L in the general population of South Korea.
Kim TH; Jo MW; Lee SI; Kim SH; Chung SM
Qual Life Res; 2013 Oct; 22(8):2245-53. PubMed ID: 23224560
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
